Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior
Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement.
Aelis, clinical-stage French biotech zeroed in on brain disorders, will receive an upfront payment of USD 30 million from addiction-focused pharmaceutical company Indivior in a combined effort on cannabis use disorders such as cannabis-induced psychosis.
Indivior is betting on the cannabis growth industry as it looks to cash in on the seven-year development of Aelis’ lead candidate, AEF0117. The drug is a synthetic sig...
